AI Therapy and the EU AI Act: What Providers Must Do to Comply

The EU AI Act treats AI systems used for therapy or emotional support with heightened scrutiny because of the potential for significant harm. The overview of obligations highlights that such systems can trigger multiple regulatory requirements: classification as high-risk or subject to specific prohibited practices depending on function and claims, conformity assessments, comprehensive risk-management systems, and stronger transparency and human-in-the-loop controls.

For businesses offering AI-based therapy or emotional support-whether as standalone apps, embedded features in health platforms, or via general-purpose models-this translates into concrete obligations. These include technical documentation and model cards, robust training and validation data practices, ongoing post-market monitoring, demonstrable human oversight mechanisms, explicit informed consent flows, and mechanisms for redress. Additionally, any therapeutic claims may push providers into regulated medical device pathways or require clinical validation under separate frameworks.

Leaders should treat regulatory compliance as product strategy. Immediate actions: map each AI feature to EU AI Act categories; inventory data sources and perform bias and safety audits; limit system capabilities or public claims until compliance is demonstrable; and design human escalation paths and emergency response protocols. Work with legal and clinical partners to determine whether additional medical device compliance is necessary.

Longer term, investing in explainability, robust logging, and interoperability will reduce friction with regulators and build user trust. Providers that proactively embed governance, clinical oversight, and transparent user education will have a competitive advantage in a market where regulatory conformity and ethical safeguards become purchasing criteria.